How to implement ICH Q3D of elemental impurities in 5 steps
|
|
- Helen Price
- 6 years ago
- Views:
Transcription
1 How to implement ICH Q3D of elemental impurities in 5 steps
2 Directive ICH Q3D aims to limit the presence of potentially toxic elemental impurities (also known as heavy metals) in pharmaceutical products intended for human use. This directive is linked to changes in the pharmacopoeias (Ph.Eur. & USP) with the introduction of new, safer, more selective and precise analytical methods with greater reproducibility and better recovery. DEADLINE INFORMATION June 2016 December 2017 ICH Q3D applicable to new products ICH Q3D applicable to licensed products
3 INDEX 1. STEP 1 - BASELINE INFORMATION 2. STEP 2 - DEFINITION OF STRATEGY TO FOLLOW 3. STEP 3 - ANALYTICAL PLAN 4. STEP 4 - CONTROL STRATEGY 5. STEP 5 - LIFE CYCLE MANAGEMENT INDEX 3
4 STEP 1 - BASELINE INFORMATION One of the major challenges in the implementation of ICH Q3D is communication with suppliers. The supplier, in most cases located in another country, is not familiar with the standard and, furthermore, it is the MAH itself that has final responsibility for the implementation. This means that you must not only collate, but also check that the information provided by suppliers is valid. At this stage you have to collect all available information on those elements that could contribute to the presence of elemental impurities in the final product: Manufacturing equipment Drug Substance Elemental Impurities in drug product Water Container Closure System Excipients At this stage it is necessary to collate at least the following information: Component Information Final product Active pharmaceutical ingredient (API) Unit formula (qualitative-quantitative) Specifications Available analytical data Stability data Number of suppliers of API Information about the suppliers /Questionnaire Origin of the API Source of supply Presence of catalysts Specifications Analytical data 4 BASELINE INFORMATION
5 Excipients Number of suppliers of excipient Information about the suppliers / Questionnaire Origin of the excipient (mineral, animal, synthetic) Source of supply Presence of catalysts Specifications Literature review Analytical data Packaging material Summary of Product Characteristics / Composition Study of extractables and leachates if applicable Literature review Process (Equipment) Process flow Equipment Materials Aggressive processes at the level of kinetic energy, ph, temperature, etc... Maintenance and qualification of equipment Services Purified Water / Water for Injection Grade. Steam CIP/SIP processes Compressed air Dependence on third-parties is a critical parameter that determines the time, above all for multi-product CMO s. Therefore, facilitating the information collection work means a reduction in time and costs. Once all the information is collected and validated, we face the next big question: What strategy should I follow to implement ICH Q3D? BASELINE INFORMATION 5
6 STEP 2 - DEFINITION OF STRATEGY TO FOLLOW Well, with all the information collated and validated... What should I do? The strategy to be followed will be decided on the basis of the information available. The variability in the application of the standard depends on the API, processes, excipients, etc. The choice of one or other strategy requires a high level of expertise. A. Final product strategy Risk analysis is based on the levels present in each medicinal product plus the possible interaction with the packaging material. Excipients (Mined vs. synthetic) Drug Substance (Metal Catalysts) Elemental Impurities in drug product Facilities/Utilities (Water/Air) Focus on the end product. Manufacturing (Equipment/Process) Container Closure System (Packaging) Focus of the assessment Packaging material: Level of risk determined by the nature of the product (oral solids, liquids, suspensions, or semi-solids) and packaging material composition. Materials Element to consider ABS (acrylonitrile butadiene styrene) Mg Glass AI, Ba, Ca, Fe, Mg, Si, Zr PC (polycarbonate) Ca, Si, Zn PET (polyethylene terephthalate) Co, Sb PE (Polyethylene) AI, Ca, Cr, Pb PES (polyethersulfone) None PP (polypropylene) AI, Ti PMMA/Acrylic (polymethyl methacrylate) Ca, Mg, Si PTFE (polytetrafluoroethylene) Ca, Fe Elastomers AI, B, Ca, Mg, S, Si, Zn Multi laminaria polyolefins Cr, Pb PVC (polyvinyl chloride) Ca, Zn Silicone Si Dennis R. Jenke and coll - PDA Journal Of Pharmaceutical Science and Technology - Vol 26 No (3) 6 DEFINITION OF STRATEGY TO FOLLOW
7 First screening to establish elemental impurities of interest. Based on data from 3 commercial batches or 6 pilot batches, the EI must be translated to units of total daily amount, also taking into account the total daily amount of the medicinal product. Daily dose of EI = Impurities concentration (ug/g) per maximum daily dose (g/day) B. Components strategy The risk analysis is based on the levels of elemental impurities in each component which could contribute EI to the medicinal product. Excipients (Mined vs. synthetic) Drug Substance (Metal Catalysts) Evaluate potential contributions of elemental impurities Most likely sources Elemental Impurities in drug product Facilities/Utilities (Water/Air) Manufacturing (Equipment/Process) Container Closure System (Packaging) For some dosage forms the potential for elemental impurities is higher Risk Assessments for these three categories may be applicable to multiple products and manufacturing locations Lower Risk The component information (literature references, suppliers, in some cases extrapolation of data can be performed, analysis of some of the components). Calculate the amount of each of the EI in the components, depending on the % that is in the formulation and based on a maximum daily dose of the medicinal product. The level of each EI is to be determined as the sum of the contribution of each component so as to determine the final amount in the medicinal product. Amount of EI in the medicinal product = n Ci x Mi i=1 The choice of one or other strategy will depend on the needs and resources of each MAH. Each case is different; therefore an expert should advise on the pros and cons of each strategy. OK, so once the information is obtained and validated and the strategy determined, what is it necessary to analyse? What procedures are used? DEFINITION OF STRATEGY TO FOLLOW 7
8 STEP 3 - ANALYTICAL PLAN Once the information is compiled and validated, and the strategy for the implementation of directive ICH Q3D on Elemental Impurities is defined, a few aspects of the analytical plan have to be considered: The analytical procedures will be based on some of these methods: Procedure 1: ICP-AES/OES Procedure 2: ICP-MS Alternative procedure: e.g. Flame - AA, Graphite - AA, Cold Vapor Atomic Absorption Spectroscopy (CVAAS) - Hg, may be used provided that they are validated. ICP - MS ICP - OES Graphite - AA Flame - AA AA - GH Price It is necessary to take the decision to perform the analyses internally or by a third party (CRO): issues to consider: Required investment: facilities, equipment, etc. Difficulty for inexperienced analysts. Sample digestion / sample preparation can be problematic during the development of methods. Scope of the analytical plan: What elements do I have to analyse? How many samples do I have? What volume of samples do I have? What level do I want to reach? Which analytical technique is the most appropriate? What is the associated cost? 8 ANALYTICAL PLAN
9 Analytical testing: Screening & Validation: In some cases, finished product or raw materials would require screening with an appropriate technique: ICP-MS is the preferred technique (lowest detection limits achieved) Drawbacks of ICP-MS are the requirements of highly equipped facilities and trained personnel, as well as high costs associated to mainteinance. When testing, the ICH Q3D requires that the screening is performed in at least 3 representative batches produced in an industrial scale or at least 6 representative batches produced in a pilot scale. Costs can be reduced through an appropriate selection of the elemental impurities to be tested as well as the analytical methodology to apply. All the methods used for analytical testing of elemental impurities must be validated, but the extent of the validation should be fitted to the intended purpose (i.e. screening test for a risk assessment would require validation for the limit of quantification, specificity and recovery data; whereas a screening to comply with a specification as control strategy would require full validation information such as robustness, accuracy, precisión, etc.) We offer the best service with our partner Kymos Laboratories, which is a GMP, EU and FDA certified analytical lab with a vast experience in this topic. Testing itself is not acceptable as a risk assessment: A scientific risk assessment determines the potential risk of variability in the obtained results and batches tested. Therefore, testing provides useful information for the risk assessment but it cannot substitute it! Subsequent to screening and risk analysis further development and validation of the method may be necessary for some elemental impurities. ANALYTICAL PLAN 9
10 STEP 4 - CONTROL STRATEGY In the case of the presence of any elemental impurity, its significance is considered on the basis of its determined or predicted value and compared with its PDE value. ICH Q3D establishes a control limit of 30% of the PDE value for each elemental impurity. At this stage the maximum concentration value must be defined from the PDE value according to the different conversion strategies (1, 2A, 2B and 3) defined in ICH Q3D. The following table shows the actions to perform according to the value obtained. EI estimated at the end of the RA Actions Control strategy EI not present Document No action required EI < 30% PDE Not additional action to be implemented Adequate existing controls 30% PDE < EI < PDE Define additional controls to control those that do not exceed the PDE level Specification on the medicinal product or components (API and excipients) Modification of the manufacturing process that provides decrease in EI Selection of the most appropiate packaging materials EI > PDE Define additional reduction controls or Evaluate the patient s safety and establish a rationale to justify higher EI content In some cases it could be acceptable Justify before health authorities ICH Q3D requires re-evaluation when there is any change in the manufacturing or packaging process, changes of suppliers, or in the facilities. 10 CONTROL STRATEGY
11 STEP 5 - LIFE CYCLE MANAGEMENT If ICH Q3D has made one thing clear, it s that it is in no way elementary. The implementation of this directive is a living process that the MAH should always bear in mind. With increasing the knowledge of the product and its process, new developments, modifications and/or variations throughout the life of the product up to its future discontinuation, the study of elemental impurities in today s product will form part of the quality system, change controls and continuous improvement on the part of the holder. In the case of changes to the product and/or components which are potential sources of elemental impurities, it must be re-evaluated. These changes may be (but not limited to): Changes to synthesis route. Changes of manufacturers. Changes in the processes. Changes to the packaging materials Facilities. All of these changes will be subject to change controls and if necessary, regulatory variations. LIFE CYCLE MANAGEMENT 11
12 We design and develop tailored made action plans to implement this guideline Azierta is corporate member of EUROTOX and comprised by a multidisciplinar team of qualified toxicologists and acreditted by EUROTOX and VISIT US ON: Azierta Toxicological Experts Competitive prices Experience (More than 1000 reports) Available database of 1500 APIs and Excipients Integral service (End to end solution) CONTACT US ACROSS EUROPE Alberto Carazo toxreports@azierta.eu Maas & Peither AG Schopfheim (Deutschland) Cynthia Schulz cynthia.schulz@gmp-verlag.de KYMOS PHARMA SERVICES Barcelona (Spain) Martí Monràs mmonras@kymos.com SOCOSUR Suresnes (France) Matthieu Chareyre scs@socosur.eu Azierta. Pozuelo de Alarcón, Madrid, June 2017.
13
Impact of New ICH Q3D and USP <232> Guidelines for Elemental Impurities Analyses
Impact of New ICH Q3D and USP Guidelines for Elemental Impurities Analyses Content Background... 2 Why should the amounts of elemental impurities be controlled in drug products?... 2 Regulatory requirements...
More informationICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon
ICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon 9 November 2016 Disclaimer The views and opinions expressed in this presentation are those of the author
More informationCase study 2: Parenteral Drug Product
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 Purpose of Case Study 2: The following case study provides one example of a summary of an elemental impurities risk
More informationElemental impurities impact on APIs
Regulatory Expectations on impurities in Drug Substances: Authority and Industry perspective Pavia, 2nd October 2015 Elemental impurities impact on APIs October 2 nd 2015 Annalisa Scali RegulatoryAffairsManager
More informationWhy Q3D? Elemental Impurities: Is Your Company Prepared for ICH Q3D
Elemental Impurities: Is Your Company Prepared for ICH Q3D J. Skutnik-Wilkinson VP NSF Health Sciences Pharma Biotech Q3D EWG member Quality Session 2 May 13, 2014 Why Q3D? Pharmacopoeias going in different
More informationICH Q3D. Questions & Answers Q1: Q2: U n d e r s ta n d i n g the Risk Assessment Requirements. Knowing the Options
ICH Q3D Questions & Answers Understanding the Risk Assessment Requirements Knowing the Options Controlling for Elemental Impurities Responsibilities U n d e r s ta n d i n g the Risk Assessment Requirements
More informationImplementation of the ICH Q3D guideline in the Ph. Eur.
Implementation of the ICH Q3D guideline in the Ph. Eur. PQRI/USP Workshop, USP Meeting center 9-10 November 2016 Bruno Spieldenner, Ph. Eur. division, EDQM Elemental impurities in the Ph. Eur. A (r)evolution
More informationDevelopment of Elemental Impurity risk assessments for existing prescription products
Development of Elemental Impurity risk assessments for existing prescription products Mark G. Schweitzer, Ph.D. Global Head, Analytical Science & Technology Novartis Technical Operations Quality 2-3 November
More informationElemental Impurities Regulations View from a CRO
White Paper Elemental Impurities Regulations View from a CRO Author: Alan Cross, Technical Specialist November 2016 1 www.rssl.com Abstract Regulatory control of elemental impurities in pharmaceutical
More informationHow to build a good CEP application - ICH Q3D
How to build a good CEP application - ICH Q3D Lisa Moore B.Sc. (Pharm), MPSI Pharmaceutical Assessor, HPRA, Ireland External Expert CEP assessor. The place of the Certification Procedure in the global
More informationImplementation of the ICH Q3D guideline in the Ph. Eur.
Implementation of the ICH Q3D guideline in the Ph. Eur. PQRI/USP Workshop, USP Meeting center 2-3 November 2017 Mr Bruno Spieldenner, European Pharmacopoeia, EDQM Elemental impurities in the Ph. Eur. A
More informationElemental Impurities: An Industry Perspective
Elemental Impurities: An Industry Perspective Ernest Parente, PhD Mallinckrodt Pharmaceuticals May 17, 2016 2016 GPhA CMC Workshop Overview Risk Assessment The Supplier Interface The Contractor Interface
More informationAPI Testing Requirements to Support the EI Risk Assessment. Elisabeth Corbett Associate Director, GRS-CMC, Bristol-Myers Squibb November 9, 2016
API Testing Requirements to Support the EI Risk Assessment Elisabeth Corbett Associate Director, GRS-CMC, Bristol-Myers Squibb November 9, 2016 Agenda Background Review of ICH Q3D Risk Assessment Principles
More informationEU Regulatory Perspective and Expectations. Sven-Erik Hillver Senior expert, QWP delegate Medical Products Agency, Sweden
EU Regulatory Perspective and Expectations Sven-Erik Hillver Senior expert, QWP delegate Medical Products Agency, Sweden Disclaimer EU regulators still have to build up an experience of applications based
More informationPHARMACEUTICAL TESTING
WHITEHOUSE, NJ PHARMACEUTICAL TESTING Pharmaceutical Expertise for GMP & CMC Testing Our Pharmaceutical Expertise With more than 20 years of experience in a variety of industries, our Whitehouse, New Jersey
More informationElemental impurities Expectations for APIs and Excipients in the EU
Elemental impurities Expectations for APIs and Excipients in the EU Implementation strategy in the European Pharmacopoeia Dr. Ulrich Rose Head of Division A European Pharmacopoeia Department EDQM 1 Elemental
More informationImplementation of ICH Q3D in the Certification Procedure
Implementation of ICH Q3D in the Certification Procedure PQRI/USP Workshop on ICH Q3D Elemental Impurities Requirements Recent Experience and Plans for Full Implementation in 2018 November 2-3, 2017 Cristian
More informationApproaches to elemental impurity product risk assessments with limited supplier information
Approaches to elemental impurity product risk assessments with limited supplier information Mark G. Schweitzer, Ph.D. Global Head, Analytical Science & Technology Novartis Technical Operations Quality
More informationElemental Impurities Testing at a Pharmaceutical Company
Elemental Impurities Testing at a Pharmaceutical Company Nancy Lewen Research Fellow Atomic Spectroscopy Center of Excellence Chemical and Synthetic Development Bristol-Myers Squibb PRQI-USP Workshop November
More informationElemental impurities and their measurement. a: 119 Magowar Rd, Girraween 2145 p: (02) f: (02)
Elemental impurities and their measurement A change is on its way. The new millennium has brought with it a rethink of the approach to heavy metals testing in pharmaceuticals. In addition to the simple
More informationFDA Perspective on Standards and Recommendations for Control of Elemental Impurities in Drug Products
FDA Perspective on Standards and Recommendations for Control of Elemental Impurities in Drug Products AAPS Annual Meeting 27 October 2015 John F. Kauffman, Ph.D. CDER Office of Pharmaceutical Quality Division
More informationDerivation and Justification of Safety Thresholds
Derivation and Justification of Safety Thresholds Douglas J. Ball, MS, DABT Chair, PQRI L&E Toxicology Subgroup Research Fellow, Safety Sciences - Pfizer, Inc. Agenda Basic Definitions Current Regulatory
More informationAgilent Resources for Workflow Compliance MEASURING ELEMENTAL IMPURITIES IN PHARMACEUTICAL MATERIALS
Agilent Resources for Workflow Compliance MEASURING ELEMENTAL IMPURITIES IN PHARMACEUTICAL MATERIALS AGILENT SOLUTIONS USP / & ICH Q3D Implementing Elemental Impurities Tests in the Pharmaceutical
More informationEMPROVE For Raw and Starting Materials & For Filtration Devices and Single Use Systems. Jan Thomsen Warsaw, November 15 th, 2016
EMPROVE For Raw and Starting Materials & For Filtration Devices and Single Use Systems Jan Thomsen Warsaw, November 15 th, 2016 2 Content Emprove - An Introduction Emprove for Raw and Starting Materials
More informationImplementation strategy of ICH Q3D guideline
1 2 3 1 July 2016 EMA/404489/2016 Committee for Medicinal Products for Human use (CHMP) 4 5 Draft Draft agreed by QWP and BWP June 2016 Adopted by CHMP for release for consultation June 2016 Start of public
More informationImplementation of ICH Q3D in the Certification Procedure
LS/CB PUBLIC DOCUMENT (LEVEL 1) PA/PH/CEP (16) 23 Strasbourg, August 2016 Certification of suitability to the Monographs of the European Pharmacopoeia Implementation of ICH Q3D in the Certification Procedure
More informationLhasa Limited Collaborative Data & Knowledge Sharing
Lhasa Limited Collaborative Data & Knowledge Sharing Featuring: Elemental Impurities and PDE/AI Data Sharing Dr Liz Covey-Crump liz.covey-crump@lhasalimited.org Acknowledgements: Dr Crina Heghes, Dr Will
More informationElementverunreinigungen in Pharmaprodukten Neue Limits und Verfahren zur Bestimmung nach USP
Elementverunreinigungen in Pharmaprodukten Neue Limits und Verfahren zur Bestimmung nach USP Ludwig Huber, Ph.D Chief Advisor, Global FDA Compliance for Ludwig Huber Phone: +49 7902 980582 E-mail: Ludwig_Huber@Labcompliance.com
More informationEuropean reflections on reviewing NDAs and ANDAs for ICH Q3D elemental impurity compliance
European reflections on reviewing NDAs and ANDAs for ICH Q3D elemental impurity compliance Diana van Riet-Nales, Medicines Evaluation Board/NL NL CHMP/CVMP Quality Working Party delegate (humans) Former
More informationPhase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017
Phase Appropriate GMPs for IMPs Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 1 Lets start with References https://mhrainspectorate.blog.gov.uk/2016/0 5/20/manufacture-of-investigationalmedicinal-products-frequently-askedquestions/
More informationICH Q3D RISK ASSESSMENT: REGULATORY SUCCESS AND STANDARDIZED METHODOLOGY FOR NEW FILINGS WILLIAM STEVENS- MERCK & CO., INC.
ICH Q3D RISK ASSESSMENT: REGULATORY SUCCESS AND STANDARDIZED METHODOLOGY FOR NEW FILINGS WILLIAM STEVENS- MERCK & CO., INC. 02 November 2017 PQRI/USP Elemental Impurities Workshop Outline Review of Risk
More informationElemental Impurities and Animal Drugs An Update from CVM
Elemental Impurities and Animal Drugs An Update from CVM November 2, 2017 Michael Brent, Ph.D. Center for Veterinary Medicine (CVM) Division of Manufacturing Technologies (DMT) This presentation summarizes
More informationImplementation strategy of ICH Q3D guideline
08 March 2017 EMA/CHMP/QWP/115498/2017 Committee for Medicinal Products for Human use (CHMP) Draft agreed by QWP and BWP June 2016 Adopted by CHMP for release for consultation June 2016 Start of public
More informationImpurity Control in the European Pharmacopoeia
Impurity Control in the European Pharmacopoeia Training Session Zagreb, Croatia, 24-25 May, 2018 Dr Ulrich Rose Head of Division European Pharmacopoeia Department, EDQM Agenda Which impurities are controlled?
More informationTechnical requirements to Good Manufacturing Practice in metered dose inhalers production and development (2. part) Extractable - Leachable
Technical requirements to Good Manufacturing Practice in metered dose inhalers production and development (2. part) Extractable - Leachable Dr. Gyula Körtvélyessy UNIDO Honorary Secretary General of the
More informationInternational Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW
International Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW SUKHDEV SINGH *1 AND JASBIR SINGH 2 1 Rayat Institute
More informationUSP Packing General Chapters <661.1>, <381>, <665>: An Industry Perspective on Elemental Impurities Compliance for Container/Closure
USP Packing General Chapters , , : An Industry Perspective on Elemental Impurities Compliance for Container/Closure Tim Shelbourn Co-chair, IQ Consortium ICH Q3D Compliance Working Group
More informationExcipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance
Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance by Tom Savage, NSF International Since 2008, when patient deaths were first linked to
More informationUnited State Pharmacopeia: Compendial Plastic Standards: Beyond Packaging
United State Pharmacopeia: Compendial Plastic Standards: Beyond Packaging Desmond G. Hunt, Ph.D. Principle Scientific Liaison November 15, 2016 Denver, CO USP Scientific, independent, volunteer-driven,
More informationClass 1 Elements should be essentially absent Known or strongly suspected human toxicants Environmental hazards
BRIEFING 232 Elemental Impurities Limits, page 197 of PF 36(1) [Jan Feb 2010]. This revision to general chapter Elemental Impurities 232 is based on comments received during the public comment period.
More informationDr. Jianfeng Cui, Thermo Fisher Scientific, Bremen, Germany APPLICATION NOTE AN43384
APPLICATION NOTE Using graphite furnace atomic absorption to meet the requirements of elemental impurity analysis in pharmaceutical products for arsenic, cadmium and lead Dr. Jianfeng Cui, Thermo Fisher
More informationGMP considerations when designing an API plant. Presented by Cameron Roberts, Senior Engineer 4 July, 2016
GMP considerations when designing an API plant Presented by Cameron Roberts, Senior Engineer 4 July, 2016 Introduction API manufacturing is too broad a topic to cover all scenarios so I will draw from
More informationMINISTRY OF HEALTH AND SOCIAL SERVICES
MINISTRY OF HEALTH AND SOCIAL SERVICES NAMIBIA MEDICINES REGULATORY COUNCIL POST REGISTRATION AMENDMENT GUIDELINES These guidelines are meant to provide assistance to industry and health care professionals
More informationContent of the dossier for chemical purity and microbiological quality
Division Certification of Substances CP/CB PUBLIC DOCUMENT (Level 1) English only/anglais seulement PA/PH/ CEP (0) 1 R February 0 Certification of suitability of Monographs of the European Pharmacopoeia
More informationFederal Institute for Drugs and Medical Devices ICH-Leitlinie Q 8 - Pharmaceutical Development die regulatorische Perspektive
ICH-Leitlinie Q 8 - Pharmaceutical Development die regulatorische Perspektive Dr. Susanne Keitel Swiss Association for Quality Olten, 28. Juni 2006 1 Overview of the Presentation ICH Q 8: background and
More informationRegulation of Active Pharmaceutical Ingredients (API)
Regulation of Active Pharmaceutical Ingredients (API) Stephan Rönninger Head External Affairs Europe, International Quality June 21, 2013 SINDUSFARMA / ANVISA / FIP-IPS Conference, Brasilia Agenda Regulations
More informationFDA Guidance and Current Experience with New Drug Submissions
FDA Guidance and Current Experience with New Drug Submissions Danae Christodoulou, Ph.D. CDER/OPQ Office of New Drug Products This presentation reflects the views of the author and should not be construed
More informationElemental Impurities Update from CVM
Elemental Impurities Update from CVM February 19, 2014 Michael Brent, Ph.D. Center for Veterinary Medicine Division of Manufacturing Technologies, HFV-146 USP and The elemental impurity limits
More informationMedicine Variations Guideline
Medicine Variations Guideline National Health Regulatory Authority (NHRA) Kingdom of Bahrain 30 th March 2017 Version 2.0 Chief of Pharmaceutical Product Regulation: Dr/Roaya Al Abbasi Date: NHRA CEO Approval:
More informationPharmaceutical Packaging Materials Quality Control and USP Compliance: Agilent Cary 630 FTIR
Pharmaceutical Packaging Materials Quality Control and USP 661.1 Compliance: Agilent Cary 63 FTIR Application Note Pharmaceutical Testing and Research Author Frank Higgins Agilent Technologies, Inc. Introduction
More informationMedicines Variations Guideline
Medicines Variations Guideline National Health Regulatory Authority (NHRA) Kingdom of Bahrain 27/08/2014 Version 1.1 Chief of Pharmaceutical Product Regulation: Dr / Roaya Al Abbasi Date: NHRA CEO Approval:
More informationVIEW POINT. Approach to The Elemental Impurities Risk Assessment in Pharmaceuticals
VIEW POINT Approach to The Elemental Impurities Risk Assessment in Pharmaceuticals What are Elemental Impurities? The elemental impurities are the impurities which get introduced into the final drug product
More informationGeneral concepts in the Ph. Eur.: theory and rationale
General concepts in the Ph. Eur.: theory and rationale General Notices, General Chapters and General Monographs Cathie Vielle Head of European Pharmacopoeia Department The structure of the Ph. Eur. 2 General
More informationGuidance for Industry Q3B(R2) Impurities in New Drug Products
Guidance for Industry Q3B(R2) Impurities in New Drug Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics
More informationRegulatory expectations on impurities in drug substances - Pavia, October 2, Luisa Torchio Euticals SpA
Regulatory expectations on impurities in drug substances - Pavia, October 2, 2015 Luisa Torchio Euticals SpA An Impurity is defined as any substance or element present in a drug substance (DS) that is
More informationGLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE
GLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE Finished Pharmaceutical Product Questionnaire This questionnaire is used to collect information from vendors with regards to finished pharmaceutical products
More informationIndustry Perspective on Manufacturing in Early Development
Industry Perspective on Manufacturing in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Eric Schmitt AbbVie IQ Drug Product Manufacturing Working Group August 2012 issue of Pharmaceutical
More informationPHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME. PI July 2018
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 045-1 1 July 2018 GUIDELINES ON THE FORMALISED RISK ASSESSMENT FOR ASCERTAINING THE APPROPRIATE GOOD MANUFACTURING
More informationHealth Canada's Experience When Implementing the ICH Q3D Elemental Impurity Guidance for NDSs and ANDSs
Health Canada's Experience When Implementing the ICH Q3D Elemental Impurity Guidance for NDSs and ANDSs Alison Ingham PQRI/USP Elemental Impurities workshop 9 November 2016 Introduction Health Canada is
More informationAgilent Atomic Spectroscopy Solutions for Energy & Chemicals AA, MP-AES, ICP-OES, ICP-MS.
Agilent Atomic Spectroscopy Solutions for Energy & Chemicals AA, MP-AES, ICP-OES, ICP-MS. 1 Agilent Technology Leadership, the first 55 years 1957 Built components for world's first AA (as Techtron) 1971
More informationASMF/DMF Quality Assessment Report (QAR) IGDRP Quality Working Group
ASMF/DMF Quality Assessment Report (QAR) IGDRP Quality Working Group Version Description of Change Author Effective Date v 1.0 Original publication ASMF/DMF WG May 26, 2015 v 1.1 Watermark added ASMF/DMF
More informationThe European Pharmacopoeia
The European Pharmacopoeia General methods, Control of impurities, FP monographs, Pharmacopoeial harmonisation International workshop on the Chinese and the European Pharmacopoeias The new editions Dr.
More informationThe GCC Guidelines for Stability Testing of Drug Substances and Pharmaceutical Products EDITION TWO 1428 H 2007 G
The GCC Guidelines for Stability Testing of Drug Substances and Pharmaceutical Products EDITION TWO 1428 H 2007 G (1) INTRODUCTION The following guideline defines the stability data package for a drug
More informationElemental Impurities / Metal Impurities AFFINISOL HPMCAS (Hydroxypropyl Methylcellulose Acetate Succinate)
Effective: August 14, 2017 Supersedes: December 2, 2015 Elemental / Metal AFFINISOL HPMCAS (Hydroxypropyl Methylcellulose Acetate Succinate) USP general chapter "Elemental impurities - Limits" and
More informationVALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY *)
VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY *) Guideline Title Validation of Analytical Procedures: Methodology Legislative basis Directive 75/318/EEC as amended Date of first adoption December 1996
More informationComparing an instrumental technique based on its
10 Spectroscopy 33(3) March 2018 www.spectroscopyonline.com Atomic Perspectives Choosing the Right Atomic Spectroscopic Technique for Measuring Elemental Impurities in Pharmaceuticals: A J-Value Perspective
More informationá1225ñ VALIDATION OF COMPENDIAL PROCEDURES
1640 á1224ñ Transfer of Analytical Procedures / General Information USP 39 THE ANALYTICAL PROCEDURE The procedure should be written with sufficient detail and explicit instructions, so that a trained analyst
More informationMedicines Control Authority of Zimbabwe
EFV... QUALITY INFORMATION SUMMARY (QIS) FOREWORD The Quality Information Summary (QIS) template should be completed to provide a condensed summary of the key quality information for product dossiers (PDs)
More informationCleaning / Cleaning Validation Update on toxicological approach
Cleaning / Cleaning Validation Update on toxicological approach Paul Sexton, Sarah O Meara, Denise Coakley GMP Conference 12th November 2014 Content Section I - Introduction Section II Toxicological Tool
More informationDocumentation requirements for an initial consultation
Language : French or English Documentation requirements for an initial consultation Because of the wide range of medical devices which incorporate, as an integral part, an ancillary medicinal substance,
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON SUMMARY OF REQUIREMENTS FOR ACTIVE SUBSTANCES IN PART II OF THE DOSSIER
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 28 January 1998 CPMP/QWP/297/97 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE
More informationEUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible
More informationChristine Oechslein. GMP Focus. Managing Process Validation. A Drugmaker s Guide. PDF Download. Excerpt from the GMP MANUAL
Christine Oechslein GMP Focus Managing Process Validation A Drugmaker s Guide PDF Download Excerpt from the GMP MANUAL Bibliographic Data of the Deutsche Nationalbibliothek: http://dnb.ddb.de ISBN: 978-3-95807-056-1
More informationAn Overview of IQ s Position Paper: Early Development GMPs for Small-Molecule Specifications
An Overview of IQ s Position Paper: Early Development GMPs for Small-Molecule Specifications On behalf of Specifications Team Kirby Wong-Moon, Ph.D. Amgen Inc. Best Practices and Application of GMPs for
More informationValidation/Verification of Test Methods An FDA Perspective. Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness
Validation/Verification of Test Methods An FDA Perspective Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness FD & C Act Overview Definition of drugs What cgmps are Finished Pharmaceuticals cgmp
More informationReview article Rapports De Pharmacie 2015;1(2):46-53 ISSN:
Review article Rapports De Pharmacie 2015;1(2):46-53 ISSN: 2455-0507 ABSTRACT APPLICATION OF RISK ASSESSMENT IN PRODUCT QUALITY LIFECYCLE MANAGEMENT Subin Sankarankutty Regulatory Consultant, Health Sciences
More informationAPI Stability Protocols and. Chris Byrne Tasmanian Alkaloids
API Stability Protocols and Evaluations Chris Byrne Tasmanian Alkaloids API Stability Overview APIs = 100% pure Limited (if any) degradation No interactions with other agents in drug products Less likelihood
More informationImpurities from degradation of Drug Substances
Impurities from degradation of Drug Substances REFERENCE 1. ICH - IMPURITIES IN NEW DRUG SUBSTANCES - Q3A(R2) 2. ICH - IMPURITIES IN NEW DRUG PRODUCTS - Q3B(R2) 3. ICH - VALIDATION OF ANALYTICAL PROCEDURES:
More informationBRIEFING. . Over time, 466 may be used less frequently and may be withdrawn.
Page 1 of 13 BRIEFING 1086 USP 37 page 828. As part of an ongoing monograph modernization initiative, the United States Pharmacopeial Convention (USP) is updating this general chapter, 1086 Impurities
More informationPharmaceutical Reference Standards: Overview and Role in Global Harmonization
Matthew Borer, Ph.D., Advisor Pharmaceutical Reference Standards: Overview and Role in Global Harmonization 3rd DIA China Annual Meeting Beijing, China, 16-18 May, 2011 What is a Pharmaceutical Reference
More informationOfficial Letter from the DOH
Issued Date 2009/04/02 Issued by DOH Ref. No 0980316268 RE The DOH issued an official letter to announce the implementation of the Guideline for BA/BE Studies on April 2, 2009 (Ref. No. 0980316265). Please
More informationTogether, beyond the standard. Reference standards and services for the pharmaceutical industry. lgcstandards.com/mikromol
Together, beyond the standard. Reference and services for the pharmaceutical industry QUALITY IS 9001 IS/IEC 17025 IS 17034 GMP lgc.com/mikromol Welcome to Mikromol 25 years of excellence At Mikromol,
More informationConsultation by a notified body on an ancillary medicinal substance integrated in a medical device
Consultation by a notified body on an ancillary medicinal substance integrated in a medical device Documentation requirements for an initial consultation Language : French or English Because of the wide
More informationScientific & Risk Based Compliance
www.qualitybydesign.es Scientific & Risk Based Compliance QbD Pharmaceutical Services S.L About us Mission Flexibility QbD Pharmaceutical Services S.L delivers high added-value services and specialised
More informationEurope s new approach to assurance of API quality and its implications for manufacturers and producing countries
Europe s new approach to assurance of API quality and its implications for manufacturers and producing countries IPA / EDQM / WHO Mumbai Conference 28 September 2012 Dr Florence Benoit-Guyod, EDQM Inspector,
More informationGuidance Document 01 January 2016 CONTENTS. 1. Introduction Background 1.2. Objectives 1.3. Scope and application 1.4 APIMF holder obligations
GUIDANCE ON AMENDMENTS TO AN ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) SUBMITTED IN SUPPORT OF A PREQUALIFIED PHARMACEUTICAL PRODUCT (FPP) OR PREQUALIFIED ACTIVE PHARMACEUTICAL INGREDIENT (API)
More informationSPECIFIC MONOGRAPHS. A Guide Through The Different Sections. Claude Coune
SPECIFIC MONOGRAPHS A Guide Through The Different Sections Claude Coune Claude Coune, EDQM, Council of Europe, All rights reserved, 2010 1 Contents of the European Pharmacopoeia: nearly 2100 monographs
More informationICH Guidelines Elemental Impurities: Strategies for Implementation for APIs
ICH Guidelines Elemental Impurities: Strategies for Implementation for APIs Frankfurt, October 2017 Dr. Landry Le Chevanton 1 ICH Guidelines Elemental Impurities: Strategies for Implementation for APIs
More informationICH Topic Q 3 A Impurities Testing Guideline: Impurities in New Drug Substances
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit CPMP/ICH/142/95 ICH Topic Q 3 A Impurities Testing Guideline: Impurities in New Drug Substances Step 5 NOTE
More informationQUALITY OF PROLONGED RELEASE ORAL SOLID DOSAGE FORMS
QUALITY OF PROLONGED RELEASE ORAL SOLID DOSAGE FORMS Guideline Title Quality of Prolonged Release Oral Solid Dosage Forms Legislative basis Directive 75/318/EEC as amended Date of first adoption October
More informationUSP Chapters <232> and <233> Implementation Strategy. Horacio Pappa, Ph.D. Director - General Chapters U.S. Pharmacopeia
USP Chapters and Implementation Strategy Horacio Pappa, Ph.D. Director - General Chapters U.S. Pharmacopeia Chapter Heavy Metals - Issues 1. Difficulties in reproducibility Monitor solutions/standards
More informationOn the Q&A to the Guideline for Common Technical Documents
To: Public Health Bureau Prefectural Government Letter from PFSB/ELD 22 nd October 2001 From: Evaluation & Licensing Division, Pharmaceutical & Food Safety Bureau, The Ministry of Health, Labour and Welfare
More informationPHARMACEUTICAL DEVELOPMENT
CONTENTS PHARMACEUTICAL DEVELOPMENT Table of Acronyms - Abbreviations Introduction Preface Forward VIII XIII XV XVI XVII Chapter 1 Regulatory 1.1 - Pre-formulation checklist 1.3 Documentation 1.4 - SOP
More informationGuideline on the Requirements for Quality Documentation Concerning Biological Investigational Medicinal Products in Clinical Trials
1 2 3 18 February 2010 EMA/CHMP/BWP/534898/2008 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the Requirements for Quality Documentation Concerning Biological Investigational
More information9/2/2014. USP Monograph Modernization. Todays topics. USP basic. Todays topics. - USP basic. - USP publications. - USP monograph modernization
USP Monograph Modernization Procedure Review and Development Donald Min 2 USP basic Since USP's founding in 1820, our operations have grown exponentially: from 11 volunteers collaborating from their respective
More informationUtilisation of Data as part of an Integrated EI Risk Assessment Process Role of Industry Collaboration /FDA-IPEC Excipient Study Data
Utilisation of Data as part of an Integrated EI Risk Assessment Process Role of Industry Collaboration /FDA-IPEC Excipient Study Data Andrew Teasdale PQRI/USP Workshop on Elemental Impurity Requirements
More informationRegistration and renewal of the credential certificate for registration
Registration and renewal of the credential certificate for registration 1. Qualification of the applicant: 1.1 Must be a holder of the license to manufacture or import the psychotropic substances of category
More informationTable of Contents Section 1: Section 2: Section 3: Section 4: Section 5: Section 6: Section 7:
Table of Contents Section 1: Administrative Section... 1 Section 2: Active Pharmaceutical Ingredients... 7 Section 3: Finished Pharmaceutical Product... 10 Section 4: Safety/Efficacy and/or Therapeutic
More informationApplication of PAT for Tablet Analysis. Case examples from Novartis Lorenz Liesum, Lead PAT Hamburg, 19 th of April 2013
Application of PAT for Tablet Analysis Case examples from Novartis Lorenz Liesum, Lead PAT Hamburg, 19 th of April 2013 Agenda PAT@Novartis Organization Business Drivers and Cases NIR Spectroscopy for
More informationGMP GUIDELINES. GMP Guides from Industry Organisations. FDA cgmp WHO GMP. cgmp Guide Drugs 21 CFR 210 GAMP. ISPE Technical Guides
FDA cgmp cgmp Guide Drugs 21 CFR 210 cgmp Guide Drugs 21 CFR 211 cgmp Guide Medical Device 21 CFR 808, 812, 820 cgmp Guide Biologics 21 CFR 600, 606, 610 Guideline List Human Drugs Guideline List Biologics
More information